Shicong Tang

Dr. Shicong Tang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
QWQing Wang
Qing Wang
KSKe Sun
Ke Sun
RLRui Liu
Rui Liu
YSYing Song
Ying Song
YLYafeng Lv
Yafeng Lv
STShicong Tang
Shicong Tang
Background: Breast cancer (BC) is a highly heterogeneous disease, and although immunotherapy has recently increased patient survival in a number of solid and hematologic malignancies, most BC subtypes respond poorly to immune checkpoint blockade therapy (ICB). B cells, particularly those that congregate in tertiary lymphoid structures (TLS), play a significant role in antitumour immunity. However, B‐cell heterogeneity at single‐cell resolution and its clinical significance with TLS in BC need to be explored further.Methods: Primary tumour lesions and surrounding normal tissues were taken from 14 BC patients, totaling 124,587 cells, for single‐cell transcriptome sequencing and bioinformatics analysis.Results: Based on the usual markers, the single‐cell transcriptome profiles were classified into various clusters. A thorough single‐cell study was conducted with a focus on tumour‐infiltrating B cells (TIL‐B) and tumour‐associated neutrophils (TAN). TIL‐B was divided into five clusters, and unusual cell types, such as follicular B cells, which are strongly related to immunotherapy efficacy, were identified. In BC, TAN and TIL‐B infiltration are positively correlated, and at the same time, compared with TLS‐high, TAN and TIL‐B in TLS‐low group are significantly positively correlated.Conclusions: In conclusion, our study highlights the heterogeneity of B cells in BC, explains how B cells and TLS contribute significantly to antitumour immunity at both the single‐cell and clinical level, and offers a straightforward marker for TLS called CD23. These results will offer more pertinent information on the applicability and effectiveness of tumour immunotherapy for BC.

10 December 2024 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
QWQing Wang
Qing Wang
YYYushuai Yu
Yushuai Yu
CWChenxi Wang
Chenxi Wang
ZJZirong Jiang
Zirong Jiang
JLJialu Li
Jialu Li
SCSong Chuangui
Song Chuangui

1 July 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
YLYidan Lin
Yidan Lin
YYYushuai Yu
Yushuai Yu
QWQing Wang
Qing Wang
KHKaiyan Huang
Kaiyan Huang
SGShukai Guo
Shukai Guo
SCSong Chuangui
Song Chuangui
This study developed a machine learning model for predicting the presence of tertiary lymphoid structures (TLSs) and treatment response to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC). This multicenter study retrospectively included 697 patients, including the training cohort (n = 137), the TLS validation cohort (n = 63) and the NAT response validation cohorts (n = 560). Five machine learning models were developed to predict the presence of TLSs, and the XGBoost model, which exhibited the best performance, was selected as the radiomics-based TLS (rTLS) predictive model. The rTLS predictive model demonstrated robust predictive performance, including across various patient subgroups. Prognostic analysis showed that the rTLS predictive score was significantly correlated with disease-free survival (DFS) in TNBC receiving NAT, and was identified as a strong independent prognostic factor. Pathomic features further explained the pathological heterogeneity of TNBC with different responses to NAT. Overall, the rTLS predictive model, which accurately predicted the presence of TLSs and treatment response to NAT in TNBC, held promise for future clinical application in formulating personalized strategies for TNBC, ultimately improving prognosis, aiding in individualized patient treatment.

9 February 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SXSiqi Xie
Siqi Xie
MTMingjian Tan
Mingjian Tan
HLHongwan Li
Hongwan Li
LLLv Li
Lv Li
HZHengyu Zhang
Hengyu Zhang
STShicong Tang
Shicong Tang
Background: Relevant studies suggest that serum vitamin level is related to the risk of breast cancer, and dietary pattern and drug supplementation can significantly affect the level of vitamin in the body. Therefore, intervention of vitamin level in the body is expected to be a potential strategy to reduce the risk of breast cancer. However, the current epidemiological findings of serum vitamin levels and breast cancer risk are inconsistent, and the relationship between serum vitamin and breast cancer is still controversial. In this study, we compared the serum vitamin expression levels of healthy people, benign breast patients, and breast cancer patients, and evaluated the relationship between B vitamin levels and breast cancer risk. Methods: The study used liquid chromatography-tandem mass spectrometry to determine the serum vitamin levels of 520 people who attended Yunnan Cancer Hospital from September 2020 to December 2020. After screening by exclusion criteria, 38 patients with benign breast diseases, 87 patients with breast cancer and 91 healthy controls were finally included. The kruskal–wallis H test was used to compare the differences in serum vitamin levels of subjects. Χ2 test was used to evaluate the relationship between B vitamin level and age,BMI,TNM staging,Ki-67,Her-2,surgery and chemotherapy, and other baseline characteristics and through binary logistic regression analysis, calculating odds ratio and 95% confidence interval (CI) to evaluate the relationship between B vitamins and breast cancer risk. Conclusion: The levels of VitB1 and VitB5 in the serum of breast cancer patients and patients with benign breast diseases were higher than those in the healthy control group, while the expression levels of VitB3 in breast cancer patients were lower than those in the healthy control group and the breast benign disease groups. The level of VitB1 was positively correlated with breast cancer risk. The VitB3 level was negatively correlated with breast cancer risk. The VitB5 level is not significantly related to the risk of breast cancer.

5 April 2024 in Apoptosis
Verified
Journal Article
Closed access
PDF file
STShicong Tang
Shicong Tang
QWQing Wang
Qing Wang
KSKe Sun
Ke Sun
YSYing Song
Ying Song
RLRui Liu
Rui Liu
RGRong Guo
Rong Guo

26 April 2023 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
JZJiawen Zhao
Jiawen Zhao
LZLei Zhang
Lei Zhang
YZYingzhu Zhao
Yingzhu Zhao
NWNan Wu
Nan Wu
XZXi Zhang
Xi Zhang
STShicong Tang
Shicong Tang